Rolul microbiotei în evoluția clinică a pacienților cu Scleroză Multiplă tratați cu interferon-beta: o abordare complexă

Proposal Registration CodePN-III-P1-1.1-PD-2021-0547
Project Registration CodePD 80/2022
Project AcronymMicro-MS
Purpose and project planningBy considering the gut-brain axis from four perspectives – immunity (Th1, Th2, Th17), local microbiota products (short-chain fatty acids -SCFA), vagus nerve signalling and neuroprotection (brain derived neurotrophic factor – BDNF) and loss of blood-brain barrier (BBB) integrity by matrix metalloproeinases (MMP), complex biological implications can be established between the microbiome and neuroinflammation. This complex quadri-dimensional approach based on a clinical longitudinal MS population has not been considered in clinical terms before. The direct intestinal microbiome is ephemeral and highly influenced by alimentation, therefore, plasma SCFA analysis will eliminate the most frequent bias. The project will use a highly selective QTOF LC-MS system with a purpose-developed method in order to measure plasma SCFA levels. LC-MS is a modern technique increasingly used in recent years for biomonitoring and diagnostics.Project plan:Socio-demographical and clincal assessment of study population (20 RRMS, 20 SPMS, 20 benign MS, 20 naive MS, 20 controls);Harvesting of the plasma samples;SCFA analysis by HPLC (plasma): Development of detection of acetic, propionic, butyric and caproic acids and internal standard without and after derivatization, development of HPLC separation of the analytes, development of extraction method of the analytes from plasma, performance verification of the proposed analytical method: linearity, accuracy and precision;MMP and cytokine analysis by xMAP technology. Color-coded internally-dyed magnetic beads coated with specific monoclonal antibodies bind the analytes of interest in the biological sample. After unbound antigens are washed away, the previously formed antigen-antibody complexes are tagged with a fluorescent reporter via streptavidin/avidin-biotin bridges. Analyte concentrations are determined by a 2-laser interrogation system: red laser for specificity identification based on each bead’s internal dye, and green laser for quantification of bound analytes based on reporter fluorescence intensities. Patient samples with unknown concentrations are evaluated based on a calibration curve generated in the same analytical run;BDNF by ELISA method.
Project Start Date01.04.2022
Project End Date01.04.2024
Project Duration24 months
Total Budget Value50.000 EUR
FundingMinistry of Research and Innovation, CNCS-UEFISCDI
Main ObjectivesMain Objective: To determine the influence that plasma SCFA have upon the peripheral immune processes (a selected cytokine pannel), BBB permeability (MMP), vagus nerve signalling and neuroprotection (BDNF) in different groups of MS patients (RRMS, SPMS, BMS, naïve MS phenotype) treated with IFNβ; Specific Objectives:(1) Development of detection of acetic, propionic, BA, CA and improve the internal standard of  chromatography and mass spectrometry laboratory within the Centre for Advanced Medical and Pharmaceutical Research (CCAMF), without and after derivatization by high performance liquid chromatography (HPLC) in MS patients and HC;(2) To assess the impact of microbiota in clinical evolution of MS patients treated with IFNβ;(3) To evaluate the dietary characteristics of the target population by personalised questionnaire;
Project DirectorLaura-Iulia Barcutean
Project MentorRodica Balasa
ResultsThe development of an effective method to evaluate plasma SCFA in MS patients using HPLC in order to discover if  SCFA levels as biomarkers targeted for MS population can be used as biomarkers.
Host Institution„George Emil Palade” University of Medicine, Pharmacy, Science and Technology of Targu Mures


Results:

 Achieved within 1/2022 stage

  • Coordination of a bachelor’s thesis of the student Manea Andrei, Faculty of General Medicine, entitled „Implications of nutrition in the evolution of patients with multiple sclerosis”, a thesis that was supported in the July 2022 Session, final grade 10 (Appendix 1).
  • The organization of a special session entitled: „Microbiome alterations and implications in patients with multiple sclerosis – targeting neuroinflammation from the intestinal compartment”, within the first edition of the International Conference Toward Precision Medicine in Multiple Sclerosis Management, which took place in Târgu Mureș during the 7 – October 8, 2022; with works presented in abstract indexed BDI, ISSN 2971-8171 (Appendix 2).

Laura Bărcuțean (Project manager): Potential mechanisms of immune modulation targeting the intestinal microbiota.

Rodica Bălașa (mentor): Gut-Brain axis: is MS a digestive triggered disease?

Achieved within 2/2023 stage

Supporting a workshop with the theme: „Gut-Brain Axis. The hidden agenda of autoimmune disorders – focus on multiple sclerosis” during the 27th edition of the International Congress for Students, Young Doctors and Pharmacists, Marisiensis, May 17-21, 2023, Târgu Mureș (Appendix 1)

  • Active participation in the 10th International Conference „Targeting Microbiota – Towards Clinical Revolution” which took place between October 17-19, 2023 in Venice, Italy; Linkedin (Abstract Annex 2)
  • Abstract accepted, presentation in progress at the Scientific Session of University Staff within the UMFST Days, an event that will take place on December 14-15, 2023 in Târgu Mureș, Romania; Link (Appendix 3)
  • Completed review article (Title: Investigating the immunomodulatory potential of short-chain fatty acids in multiple sclerosis), submitted for evaluation to a profile journal Q1 (Summary graphic representation of the properties of butyrate, original image from the article in Appendix 4)

Achieved within the project (01.04.2022 – 31.03.2024)

Summary of the project’s theme

According to the hygiene hypothesis, the increasing prevalence and incidence of autoimmune diseases such as multiple sclerosis (MS), particularly in industrialized countries, results from an underdeveloped immune system during the formative years. Although the studies in this aspect have not established a clear connection for the pathogenesis of MS, it prompted the investigations in intestinal microbiota and the fermentation metabolites of the commensal bacteria. The gut bacteria ferment dietary fibers to produce short and medium fatty acids (SCFA/MCFA). SCFA have demonstrated immunomodulatory properties and can transverse the blood-brain barrier and hypothetically exert their effects inside the central nervous system, by modulating inflammation and promoting neuroplasticity and remyelination. In the periphery, SCFA promote the differentiation of regulatory T lymphocytes and secretion of anti-inflammatory cytokines such as interleukin – 10. MCFA, such as caproic acid, have contrasting, pro-inflammatory effects depending on the microbial pattern of the patients. Caproic acid promotes the immune differentiation toward a pro-inflammatory phenotype, Th1 and Th17, with secretion of proinflammatory cytokines. The selective permeability of the blood brain barrier ensures that immune cells have no way of passage into the brain parenchyma. In MS, the blood-brain barrier permeability is altered and inflammatory cells pass through, exerting the inflammatory cascade leading to demyelination, neurodegeneration and axonal loss. Matrix metalloproteinases (MMPs) are a set of enzymes involved in the maintenance and structure of the endothelial cells that compose the blood-brain barrier. MMP9 in particular has been linked with destructive effects on the blood-brain barrier and also the intestinal barrier.

The gut brain axis represents a dynamic communication between the intestinal tract and the central nervous system, functioning as a bidirectional signaling pathway through which the enteric system influences the brain and vice-versa. The central element of this ecosystem is represented by the intestinal microbiota. The direct connection between the intestinal compartment and the brain is partially mediated via the vagus nerve. One of the most important neuromodulators involved in this bi-directional communication is brain-derived neurotrophic factor (BDNF), which modulates the excitability of the vagal neurons. BDNF is also highly influenced by the SCFA, particularly butyric acid. The experimental approach of the intestinal microbiota is challenging due to the multitude of short-term influencing factors such as alcohol consumption, diet, treatment with pre/pro biotics, stress, unhealthy diet, etc.

Therefore, the present project proposed two important directions of research:

  1. The analysis of inflammation biomarkers from a quadri dimensional perspective (see schematic below):
    • Intestinal compartment: assessment of peripheral levels of SCFA/MCFA
    • Interaction between the gut and the brain via the vagus nerve: BDNF
    • Pro and anti-inflammatory cytokines
    • Integrity of the blood-brain barrier: MMP
  1. Implementing and validating a working method by liquid chromatography-mass spectrometry (LC-MS/MS) to assess SCFA and MCFA from serum samples

Concrete achievements

  1. Implementation and validation of a working method for LC-MS/MS which allowed for the analysis of SCFA and MCFA from human serum, namely acetic acid, propionic acid, butyric acid and caproic acid, metabolites of the human microbiome with demonstrated immunomodulatory effects in MS. The method was developed and applied in the Center for Advanced Medical and Pharmaceutical Research, CCAMF (https://eeris.eu/ERIF-2000-000C-0801) from the George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures.

The development and validation of a selective, sensitive, precise, and accurate LC-MS method within this project enable the conduct of various types of future clinical, preclinical, biomonitoring, or metabolomic studies at reduced costs and with short analysis times, also allowing for efficient planning of such studies.

  1. Publications: (1) ISI-Q1 (published – review): Barcutean L, Maier S, Burai-Patrascu M, Farczadi L, Balasa R. The Immunomodulatory Potential of Short-Chain Fatty Acids in Multiple Sclerosis. Int J Mol Sci. 2024; 25(6):3198. https://doi.org/10.3390/ijms25063198. FI: 5.6.; (2) ISI-Q2 (published – original research): Barcutean L, Maier S, Bajko Z, Stoian A, Mosora O, Sarmasan Emanuela, Manescu I-B, Balasa R. Long-Term Disability Outcomes in Relapsing–Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression. J Clin Med. 2024; 13:1813. https://doi.org/10.3390/jcm13061813, IF: 3.9.; (3) ISI-Q1 (under review): sent to IJMS, manuscript ID 2956963, title: Peripheral fatty acids dynamics in response to interferon beta treatment in naïve multiple sclerosis patients: insights into inflammation, gut-brain connection and blood-brain permeability.
  2. Organisation of a special session dedicated to microbiota within an international conference:
    • Microbiome alterations and implications in patients with multiple sclerosis – targeting neuroinflammation from the intestinal compartment; International Conference: Toward Precision Medicine in Multiple Sclerosis Management, 7-8 Oct 2022, Targu Mures, Romania
      • Presented papers:
        1. Rodica Balasa: Gut-brain axis: is MS a digestive triggered disease?
        2. Anca Negovan: Environmental risk factors altering the intestinal microbiota
        3. Monica Tarcea, Gliga Florina: Diet and gut microbiota implications in multiple sclerosis
        4. Laura Barcutean, Lenard Farczadi, Rodica Balasa: Potential mechanisms of immune modulation targeting the intestinal microbiota
        5. Adina Hutanu: Inflammatory biomarkers for microbiota dysregulation in multiple sclerosis
        6. Farczadi Lenard, Laura Barcutean, Silvia Imre: The role of liquid chromatography-mass spectrometry in modern medicine – assessing the impact of microbiota by short-chain fatty acids assay
  3. Active presentations in national and international conferences in the field of research:
    • Oral presentation in the 10th World Congress of the International Society of Microbiota: Targeting Microbiota, Towards Clinical Revolution, Venice, 17-19 Oct, Italy with the paper: “The role of microbiome in multiple sclerosis: a multidimensional approach
    • Oral presentation in the Scientific Session of University Academic Staff with the paper “The role of brain-derived neurotrophic factor in interferon beta-treated multiple sclerosis patients”, 11-15 Dec, Targu Mures, Romania
    • Accepted abstract (poster, will be presented) in the 10th Congress of the European Academy of Neurology, 29 Jun – 2 July, Helsinki, Finland with the paper: “Brain-derived neurotrophic factor and progression in multiple sclerosis.
    • Accepted abstract (oral presentation) in the The 22nd Congress of the Romanian Society of Neurology, 5-7 June 2024 with the paper: “Microbiota and Multiple Sclerosis”.
  1. Student’s master and bachelor’s degree
    • I coordinated the bachelor’s degree for the student Andrei Manea, Faculty of General Medicine, within George Emil Palade University of Medicine, Pharmacy, Science and Technology, with the title “Implications of nutrition in the evolution of patients with multiple sclerosis”.The thesis was presented in July 2022, final grade 10.
    • I am coordinating a master’s thesis for the student Andreea Kelemen, master student in the program Clinical and Community Nutrition, within the George Emil Palade University of Medicine, Pharmacy, Science and Technology, with the title “Dietary Considerations for Individuals with Multiple Sclerosis”.
  2. Student dedicated workshop
    • I coordinated the first workshop for medical students within the XXVIIth International Congress for Students, Young Doctors and Pharmacists, Mariensis, in Targu Mures regarding the implications of gut-brain axis in demyelinating diseases, with a focus on MS, entitled: “Gut-brain axis. The hidden agenda of autoimmune disorders – focus on multiple sclerosis”, which took place on 17-21 may 2023, Targu Mures, Romania
    • The 2nd workshop entitled “Microbiota in multiple sclerosis: truth or dare?” has been announced and will be held on 23th of May, in Targu Mures, Romania, within the XXIIIth International Congress for Students, Young Doctors and Pharmacists, Marisiensis.

Informații generale

Domeniu:

sănătate

Valoare proiect:

50.000 EUR

Director de proiect / Responsabil partener:

Laura-Iulia Barcutean

Perioada de implementare:

01.04.2022 - 01.04.2024

Website: